{"classes":[{"categories":[{"measurements":[{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG003","spread":"NA","value":"NA"},{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below lower limit of quantification (LLOQ).","groupId":"OG004","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.1","value":"99400"},{"groupId":"OG001","spread":"50.9","value":"103000"},{"groupId":"OG002","spread":"53.3","value":"81800"},{"groupId":"OG003","spread":"59.4","value":"64900"},{"groupId":"OG004","spread":"6634.0","value":"29000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"comment":"Geometric Coefficient of Variation could not be calculated due to insufficient number of participants.","groupId":"OG000","spread":"NA","value":"95500"},{"comment":"Geometric Coefficient of Variation could not be calculated due to insufficient number of participants.","groupId":"OG001","spread":"NA","value":"200000"},{"groupId":"OG002","spread":"337.7","value":"68400"},{"comment":"Geometric Coefficient of Variation could not be calculated due to insufficient number of participants.","groupId":"OG003","spread":"NA","value":"146000"},{"groupId":"OG004","spread":"94.7","value":"154000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"comment":"Geometric Coefficient of Variation could not be calculated due to insufficient number of participants.","groupId":"OG000","spread":"NA","value":"94500"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"83.9","value":"38400"},{"comment":"Geometric Coefficient of Variation could not be calculated due to insufficient number of participants.","groupId":"OG001","spread":"NA","value":"27000"},{"comment":"Geometric Coefficient of Variation could not be calculated due to insufficient number of participants.","groupId":"OG002","spread":"NA","value":"101000"},{"comment":"Geometric Coefficient of Variation could not be calculated due to insufficient number of participants.","groupId":"OG004","spread":"NA","value":"117000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"Cycle 6 Day 1"},{"categories":[{"measurements":[{"comment":"Geometric Coefficient of Variation could not be calculated due to insufficient number of participants.","groupId":"OG000","spread":"NA","value":"71900"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Cycle 7 Day 1"},{"categories":[{"measurements":[{"comment":"Geometric Mean and Geometric Coefficient of Variation could not be calculated because the values were below LLOQ.","groupId":"OG000","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Cycle 12 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"description":"Observed serum concentrations of mezagitumab was reported.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received TAK-981 60 mg, infusion, intravenously, twice weekly on Days 1, 4, 8, 11 and 15, and mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15 and 22 during Cycles 1 and 2, then once every 2 weeks during Cycles 3 through 6, further once every 4 weeks, until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG000","title":"Phase 1b, Part 1: TAK-981 60 mg BIW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 90 mg, infusion, intravenously, twice weekly on Days 1, 4, 8, 11 and 15, and mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15 and 22 during Cycles 1 and 2, then once every 2 weeks during Cycles 3 through 6, further once every 4 weeks, until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG001","title":"Phase 1b, Part 1: TAK-981 90 mg BIW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 90 mg, infusion, intravenously, in combination with mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15, 22 during Cycles 1 and 2, then every 2 weeks during Cycles 3 through 6, further once every 4 weeks until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG002","title":"Phase 1b, Part 1: TAK-981 90 mg QW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 120 mg, infusion, intravenously, twice weekly on Days 1, 4, 8, 11 and 15, and mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15 and 22 during Cycles 1 and 2, then once every 2 weeks during Cycles 3 through 6, further once every 4 weeks, until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG003","title":"Phase 1b, Part 1: TAK-981 120 mg BIW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 120 mg, infusion, intravenously, in combination with mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15, 22 during Cycles 1 and 2, then every 2 weeks during Cycles 3 through 6, further once every 4 weeks until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG004","title":"Phase 1b, Part 1: TAK-981 120 mg QW + Mezagitamab 600 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Safety analysis set included participants who received at least 1 dose, even if incomplete, of study drug. Here \"number analyzed\" signifies participants evaluable at specified time-point.","reportingStatus":"POSTED","timeFrame":"Cycles 1, 2, 3, 4, 6, 7 and 12: Day 1 pre-dose and at multiple timepoints (up to 24 hours) post-dose (Cycle length = 28 days)","title":"Phase 1b, Part 1: Serum Concentration of Mezagitamab","type":"SECONDARY","unitOfMeasure":"ng/mL"}